| Nanocarriers as an emerging platform for cancer therapy D Peer, JM Karp, S Hong, OC Farokhzad, R Margalit, R Langer Nano-enabled medical applications, 61-91, 2020 | 9670 | 2020 |
| Progress and challenges towards targeted delivery of cancer therapeutics D Rosenblum, N Joshi, W Tao, JM Karp, D Peer Nature communications 9 (1), 1410, 2018 | 1802 | 2018 |
| Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target D Peer, EJ Park, Y Morishita, CV Carman, M Shimaoka Science 319 (5863), 627-630, 2008 | 580 | 2008 |
| Nanoparticle hydrophobicity dictates immune response DF Moyano, M Goldsmith, DJ Solfiell, D Landesman-Milo, OR Miranda, ... Journal of the American Chemical Society 134 (9), 3965-3967, 2012 | 481 | 2012 |
| The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation R Kedmi, N Ben-Arie, D Peer Biomaterials 31 (26), 6867-6875, 2010 | 473 | 2010 |
| Polysaccharides as building blocks for nanotherapeutics S Mizrahy, D Peer Chemical Society Reviews 41 (7), 2623-2640, 2012 | 437 | 2012 |
| Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 D Peer, P Zhu, CV Carman, J Lieberman, M Shimaoka Proceedings of the National Academy of Sciences 104 (10), 4095-4100, 2007 | 336 | 2007 |
| CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy D Rosenblum, A Gutkin, R Kedmi, S Ramishetti, N Veiga, AM Jacobi, ... Science advances 6 (47), eabc9450, 2020 | 332 | 2020 |
| Nanoparticles for imaging, sensing, and therapeutic intervention LK Bogart, G Pourroy, CJ Murphy, V Puntes, T Pellegrino, D Rosenblum, ... ACS nano 8 (4), 3107-3122, 2014 | 320 | 2014 |
| Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions TJ Anchordoquy, Y Barenholz, D Boraschi, M Chorny, P Decuzzi, ... ACS nano 11 (1), 12-18, 2017 | 310 | 2017 |
| Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models D Peer, R Margalit International Journal of Cancer 108 (5), 780-789, 2004 | 287 | 2004 |
| Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models D Peer, R Margalit Neoplasia (New York, NY) 6 (4), 343, 2004 | 262 | 2004 |
| Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response S Mizrahy, SR Raz, M Hasgaard, H Liu, N Soffer-Tsur, K Cohen, R Dvash, ... Journal of controlled release 156 (2), 231-238, 2011 | 248 | 2011 |
| RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice SS Kim, D Peer, P Kumar, S Subramanya, H Wu, D Asthana, K Habiro, ... Molecular therapy 18 (2), 370-376, 2010 | 248 | 2010 |
| Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes N Veiga, M Goldsmith, Y Granot, D Rosenblum, N Dammes, R Kedmi, ... Nature communications 9 (1), 4493, 2018 | 225 | 2018 |
| A modular platform for targeted RNAi therapeutics R Kedmi, N Veiga, S Ramishetti, M Goldsmith, D Rosenblum, N Dammes, ... Nature nanotechnology 13 (3), 214-219, 2018 | 225 | 2018 |
| RNAi-based nanomedicines for targeted personalized therapy A Daka, D Peer Advanced drug delivery reviews 64 (13), 1508-1521, 2012 | 195 | 2012 |
| Special delivery: targeted therapy with small RNAs D Peer, J Lieberman Gene therapy 18 (12), 1127-1133, 2011 | 183 | 2011 |
| Next-generation lipids in RNA interference therapeutics S Rietwyk, D Peer ACS nano 11 (8), 7572-7586, 2017 | 180 | 2017 |
| Paving the road for RNA therapeutics N Dammes, D Peer Trends in pharmacological sciences 41 (10), 755-775, 2020 | 178 | 2020 |
Jeffrey M. KarpProfessor of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Harvard-MITAdresse e-mail validée de partners.org
